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membranous vesicles secreted by cells, with important roles in
physiological and pathological processes. Recent research has
established the application of sEVs as therapeutic vehicles in
various conditions, including heart disease. However, the high
risk of off-target effects is a major barrier for their introduction
into the clinic. This study evaluated the use of modified sEVs ex-
pressing high levels of cardiac-targeting peptide (CTP) for thera-
peutic small interferingRNA (siRNA)delivery inmyocarditis, an
inflammatory disease of heart. sEVs were extracted from the cell
culturemediumofHEK293 cells stably expressingCTP-LAMP2b
(referred to as C-sEVs). The cardiac targeting ability of C-sEVs
with the highest CTP-LAMP2b expression was >2-fold greater
than that of normal sEVs (N-sEVs). An siRNA targeting the re-
ceptor for advanced glycation end products (RAGE) (siRAGE)
was selected as a therapeutic siRNA and loaded into C-sEVs.
The efficiency of cardiac-specific siRNA delivery via C-sEVs
was >2-fold higher than that via N-sEVs. Furthermore, siR-
AGE-loadedC-sEVsattenuated inflammation inboth cell culture
and an in vivomodel ofmyocarditis. Taken together, C-sEVsmay
beauseful drugdelivery vehicle for the treatmentofheart disease.
INTRODUCTION
Extracellular vesicles (EVs) are heterogeneous nanometer- to micro-
meter-sized membranous vesicles that originate from the endosome
or plasma membrane and are secreted into the extracellular space.1,2
EVs are classified into three main categories based on their size: (1)
exosomes (30–200 nm), (2) microvesicles (100–1,000 nm), and (3)
apoptotic bodies (1–10 mm).3,4 As vesicles with diameters %200 nm
co-sediment with microvesicles, EVs purified via ultracentrifugation
at 100,000  g are not the sole constituent of the exosome fraction.5
Hence, in this study, vesicles of %200 nm secreted into the extracel-
lular environment are collectively referred to as small EVs (sEVs).6
Heart disease remains amajor public health concern globally.7Myocar-
ditis, an inflammatory cardiomyopathy, is one of the leading causes of1024 Molecular Therapy: Nucleic Acids Vol. 24 June 2021 ª 2021 The
This is an open access article under the CC BY-NC-ND license (htsudden cardiac death in young adults. There are various causes of
myocarditis, including viral infections and autoimmune disease.8,10
Furthermore, COVID-19-related myocarditis has been increasingly re-
ported recently.11 While myocarditis is often spontaneously resolved,
some patients require organ transplantation.12 Unfortunately, an effec-
tive curative treatment hasnot yet beendeveloped.13,14Thus, it is imper-
ative to explore new approaches for myocarditis therapy. sEVs are
candidate vehicles for the delivery of molecules, such as DNA, RNA,
and proteins, in the treatment of heart disease as well as other condi-
tions.15,16 However, the accumulation of sEVs in off-target organs,
such as the liver, spleen, and lung, limits their therapeutic use.17–19
The selective delivery of sEVs to target organs, such as the brain or
heart, requires genetic modification.20–22 Recently, cells were manip-
ulated to express LAMP2b, an sEV membrane protein, fused to
neuron-specific rabies virus glycoprotein in order to generate sEVs
that specifically targeted the brain.23 Several other studies have also
reported the successful local delivery of cardiac-specific EVs.19,24
We previously enhanced cardiac targeting ability by 15%, using modi-
fied exosomes expressing cardiac-targeting peptide (CTP,
APWHLSSQYSRT), which specifically targets the heart.25 However,
greater targeting efficiency is required for drug delivery.
Receptor for advanced glycation end products (RAGE) contributes to
inflammatory/synaptic processes in heart disease.26 Furthermore, phar-
macological and genetic inhibition of RAGEwere both shown to relieve
myocarditis.27 In this study, we evaluated the therapeutic potential ofAuthor(s).
tp://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Characterization and cardiac-specific cellular uptake of C-sEVs without cytotoxicity in vitro
(A) Schematic representation of sEVs targeting cardiac cells. (B) Schematic representation of targeting via CTP-expressing sEVs. (C–E) TEM images (scale bar, 100 nm) (C),
size distribution (D), and zeta potential (E) of sEVs. (F) Western blot analysis of FLAG and GAPDH from stable cell lines as well as FLAG, LAMP2, Alix, and CD81 in sEVs. CTP
expression levels were indirectly quantified via the detection of FLAG expression. (G) Cell viability was measured through an MTS assay. (H) Expression of FLAG-LAMP2b in
H9C2 cells. (I) Fluorescence microscopy images of PKH26-labeled (red) sEVs in H9C2 cells. Values are expressed as mean ± SEM. *p < 0.05 (compared to N-sEVs).
www.moleculartherapy.orgCTP-expressing sEVs (C-sEV) for the delivery ofRAGE-targeting small
interfering RNA (siRNA) (siRAGE) to suppress myocarditis.
RESULTS
Generation and characterization of C-sEVs
We generated sEVs with high CTP expression for highly efficiently
targeting of the cardiac tissue. In particular, we generated several
HEK293 cell lines stably expressing CTP-tagged FLAG-LAMP2b
and purified sEVs from the culture medium. Based on CTP expres-
sion levels, the sEVs were named C-sEV L (low), M (medium), H
(high), and U (ultra), respectively. Normal sEVs without CTP expres-
sion (N-sEVs) were used as controls (Figure 1B). CTP expression
levels were quantified via FLAG-tagged LAMP2b detection. As deter-
mined by transmission electron microscopy (TEM), no differences in
morphology were observed between N-sEV and C-sEVs (Figure 1C).
Additionally, dynamic light scattering (DLS) analysis indicated thatC-sEVs and N-sEVs were similar in size (<150 nm) (Figure 1D).
To evaluate the stability of sEVs,28 their zeta potential was measured
via electrophoretic light scattering (ELS). A negative zeta potential
indicated a high grade of dispersion across sEVs. The zeta potential
of isolated sEVs was similar to previously reported values, in the
range of 14 to 18 mV (Figure 1E).29,30 Western blot analysis re-
vealed similar expression patterns of EV markers, such as Alix,
CD81, and LAMP2, between N-sEVs and C-sEVs. CTP expression
was highest in C-sEV U vesicles and the corresponding cell lysate
(Figure 1F). sEVs have been previously described as non-toxic in cells
or animals.31–33 To confirm the safety of sEVs, cell viability was
assessed via MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyme-
thoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assays in H9C2
rat cardiomyocytes treated with sEVs . There was no significant
change in cell viability after treatment with sEVs (Figure 1G). Taken
together, CTP expression did not affect the general properties of sEVs.Molecular Therapy: Nucleic Acids Vol. 24 June 2021 1025
Figure 2. Characterization and effects of siRAGE-loaded C-sEVs in a cellular model of inflammation
(A) Schematic representation of siRNA-loaded sEVs. (B) TEM images of siRAGE-loaded sEVs. H9C2 cells were treated with siRNA-loaded sEVs for 48 h. (C) Measurement of
H9C2 cell viability via MTS assays after treatment with siRAGE-loaded sEVs. (D) Fluorescence microscopy images of NC-siRNA-loaded (green) and PKH26-labeled (red)
sEVs in H9C2 cells, with cell nuclei (blue). (E) Western blot and (F) qRT-PCR analyses of H9C2 cells treated with siRAGE-loaded sEVs. H9C2 cells were treated with siRAGE-
loaded sEVs for 48 h before inducing inflammation via TNF-a treatment for 24 h. (G) Inflammation was monitored through detection of IL-6 levels in culture medium. TF,
transfection. Values are expressed as mean ± SEM. *p < 0.05 (compared to control); yp < 0.05 (compared to N-sEVs). See also Figure S2.
Molecular Therapy: Nucleic AcidsC-sEVs exhibited enhanced cardiac-specific cellular uptake
in vitro
To determine whether the cardiac cellular uptake of sEVs is depen-
dent on CTP expression levels, we treated H9C2 cells with sEVs
and harvested the cells after 24 h. As determined via western blotting,
cellular uptake of C-sEV U was significantly greater (i.e., 4-fold
higher) than that of N-sEVs (Figure 1H). Fluorescence staining of
the lipid membrane is most commonly utilized for monitoring sEV
uptake.34 In this study, PKH26 was used for lipid membrane staining
to monitor vesicle uptake by H9C2 cells. Confocal microscopy indi-
cated that the levels of C-sEV H and C-sEV U cellular uptake were
3- and 4-fold higher, respectively, than those observed for N-sEVs
(Figure 1I). Thus, we found that sEV cellular uptake into H9C2 cells
increased with the sEV CTP expression level.
Characterization of siRNA-loaded sEVs
Bangert et al.35 reported that knockdown of RAGE protects against
inflammatory heart disease. Accordingly, siRAGE was selected to
evaluate the therapeutic effect of C-sEV-mediated siRNA delivery
in inflammatory heart disease. First, the ratio of siRNA to sEVs
was determined in order to establish optimal conditions for
maximum association (Figure S1A). As shown in Figure S1A, siR-
AGE at 600 pmol was loaded into sEVs (40 mg) (Figure 2A).
TEM, DLS, ELS, and MTS assays were performed to evaluate the ef-
fect of siRAGE loading on sEV properties. sEVs loaded with siR-
AGE had similar morphology (Figure 2B), size, and zeta potential
(Figures S1B and S1C) compared to their non-loaded counterparts.1026 Molecular Therapy: Nucleic Acids Vol. 24 June 2021Furthermore, siRAGE-loaded sEVs were non-toxic to cells (Fig-
ure 2C). Overall, the general characteristics of sEVs were main-
tained after siRAGE loading.C-sEVs loaded with siRNA exhibited enhanced cardiac-specific
cellular uptake in vitro
To assess whether cardiac-targeted siRNA delivery was enhanced
via C-sEVs, PKH26-labeled sEVs (red) were loaded with fluores-
cence-labeled negative control siRNA (NC-siRNA, green). H9C2
cells were then treated with sEVs loaded with NC-siRNA, and
cellular uptake of NC-siRNA was visualized using confocal
microscopy after 24 h. We observed the delivery of NC-siRNA
to cells via sEVs, with 2- and 3-fold higher uptake efficiency in
the C-sEV H and C-sEV U groups, respectively, compared to the
N-sEV group (Figure 2D). To evaluate RAGE knockdown effi-
ciency via sEV-mediated siRAGE delivery, H9C2 cells were
treated with siRAGE-loaded sEVs for 48 h. Western blot analysis
revealed that RAGE silencing was 3-fold more effective in the C-
sEV U-treated group than in the N-sEV-treated group (Figure 2E).
Quantitative reverse transcription polymerase chain reaction (qRT-
PCR) indicated significantly lower RAGE expression in the C-sEV-
treated group compared to the N-sEV-treated group. In particular,
knockdown efficiency was 6-fold greater in the C-sEV U-treated
group than in the N-sEV-treated group (Figure 2F). These
results suggested that C-sEVs efficiently deliver siRNAs to
cardiomyocytes.
Figure 3. In vivo cardiac targeting of C-sEV U without cytotoxicity
(A) H&E staining of the heart, liver, lung, kidney, and spleen 2 days after sEV treatment. (B) Representative near-infrared fluorescence (NIRF) images (overlaid on photograph)
of hearts from rats administered PBS or PKH26-labeled sEVs. (C) Quantification of fluorescence intensity in the heart. (D) Representative NIRF images (overlaid on
photograph) of rat organs. (E) Quantification of fluorescence intensity in the liver, lung, kidney, and spleen. (F and G) Western blot analysis (F) and qRT-PCR detection (G) of
RAGE in heart tissue from rats treated with siRAGE-loaded sEVs. (H) qRT-PCR of RAGE mRNA in the liver, lung, kidney, and spleen. Values are expressed as the mean ±
SEM. *p < 0.05 (compared to PBS); yp < 0.05 (compared to N-sEVs). See also Figure S3.
www.moleculartherapy.orgsiRAGE-loaded C-sEVs suppressed inflammation in an in vitro
model
A model of tumor necrosis factor (TNF)-a-induced inflammation in
H9C2 cells was used to evaluate the effect of siRAGE-loaded sEVs.
H9C2 cells were treated with siRAGE-loaded sEVs for 48 h before
the induction of inflammation via treatment with TNF-a for 24 h.
Enzyme-linked immunosorbent assay (ELISA) results revealed a
sharp increase in the levels of interleukin (IL)-6, a pro-inflammatory
cytokine, in the TNF-a-treated group. However, IL-6 levels were
significantly lower in the C-sEV H/U-treated groups compared to
N-sEV-treated group (Figure 2G). Western blot analysis indicated
marked decreases in the levels of inflammatory markers, such as
RAGE, IL-6, TNF-a, COX2, HMGB1, and phosphorylated (p-)p65/
p65, in the C-sEV U-treated group (Figure S2A). Thus, siRAGE deliv-
ery via C-sEV U relieves inflammation in TNF-a-treated H9C2 cells.
Cardiac specificity of C-sEVs
After identification of C-sEV U as the most efficient cardiac-targeting
carrier in vitro, we performed in vivo experiments to confirm this.
First, we investigated whether siRAGE-loaded sEVs induce system-
atic toxicity in wild-type Sprague-Dawley (SD) rats. sEVs (100 mgof total protein in sEV precipitate resuspended in 0.5 mL of PBS
per rat) or an equal volume of PBS (0.5 mL) were administered via
tail vein injection, and rats were sacrificed 24 h later. No pathological
changes were observed in any examined organ (Figure 3A). To assess
the specific accumulation of siRAGE-loaded sEVs in the heart, we
studied the in vivo distribution of PKH26-labeled sEVs using an
in vivo imaging system (IVIS). Fluorescence intensity within the
hearts of C-sEV U-injected rats was 200% higher than that observed
in N-sEV-injected animals (Figures 3B and 3C). In contrast, with the
exception of the liver, fluorescence intensity in other organs (i.e.,
spleen, lungs, and kidneys) was significantly higher in the N-sEV-in-
jected group (Figures 3D and 3E). These results suggested that C-sEV
U accumulates efficiently within the heart and has greater cardiac
specificity than N-sEV.
C-sEVs exhibited enhanced cardiomyocyte-specific uptake
in vivo
To determine the target cell type of C-sEV U in cardiac tissue, immu-
nohistochemistry was performed with cardiomyocyte-specific (car-
diac troponin I [cTnI]), cardiac fibroblast-specific (vimentin), and
endothelial cell-specific (von Willebrand factor [vWF]) antibodies.Molecular Therapy: Nucleic Acids Vol. 24 June 2021 1027
Molecular Therapy: Nucleic AcidsPKH26-labeled C-sEV U co-localized with cTnI, but not with vimen-
tin and vWF (Figure S3). Taken together, these results indicated that
C-sEV U is effectively distributed in cardiomyocytes in vivo.Cardiac-specific siRAGE delivery efficiency of C-sEVs in vivo
Next, we investigated the in vivo RAGE knockdown efficiency via
sEV-mediated systemic siRNA delivery. Western blot analysis re-
vealed that RAGE silencing within cardiac tissues was more effective
in the siRAGE-loaded C-sEV U-injected group than in the siRAGE-
loaded N-sEV-injected group (Figure 3F). Similar results were ob-
tained at the mRNA level via qPCR analysis (Figure 3G). Conversely,
with the exception of the liver, RAGE mRNA levels in other organs
(spleen, lungs, and kidneys) were lower in the siRAGE-loaded N-
sEV-injected group than in the siRAGE-loaded C-sEV U-injected
group (Figure 3H). These results indicated that the efficiency of
siRNA delivery to heart tissue was higher for C-sEV U than for N-
sEVs.C-sEVs loaded with siRAGE suppressed inflammation in
experimental autoimmune myocarditis (EAM)
To determine whether the newly developed siRNA delivery tool could
be used to treat myocarditis, we administered siRAGE-loaded sEVs in
a widely used rat model of EAM. We compared the effects of siRAGE
delivery by C-sEV U and N-sEVs. Twenty-one days after initial im-
munization with cardiac myosin, we performed histological analyses
of left ventricular tissues. siRAGE-loaded C-sEV U prevented inflam-
matory cell infiltration in EAM, and lower inflammation was
observed in the siRAGE-loaded C-sEV U-injected group compared
to siRAGE-loaded N-sEV-injected group (Figure 4A). Echocardiog-
raphy revealed better heart function in siRAGE-loaded C-sEV U-in-
jected rats compared to that of their siRAGE-loaded N-sEV-injected
counterparts (Figure 4B). Western blot analysis indicated significant
reductions in the levels of RAGE, IL-6, TNF-a, COX2, HMGB1, and
p-p65/p65 in the former (Figure 4C). Taken together, C-sEV U effi-
ciently delivered therapeutic siRNA to the heart, demonstrating their
potential as a drug delivery tool in cardiac disease.DISCUSSION
In this study, we established four cell lines with different levels of
CTP-LAMP2b expression. As the expression level of CTP-LAMP2b
increased, so did the cardiac-specific cellular uptake of sEVs (Fig-
ure 1). In H9C2 cells, the cardiac targeting efficiency was 4-fold higher
for C-sEV U than for N-sEVs (Figure 1). Furthermore, we observed a
2-fold increase in cardiac-specific accumulation for C-sEVs in rats,
without toxicity (Figure 3).
Although we have previously demonstrated the efficiency of cardiac-
targeting sEVs, the therapeutic effects of siRNA-loaded sEVs have not
been evaluated. Thus, we delivered siRAGE to inflammatory H9C2
cells and rats with myocarditis via C-sEVs. siRNA knockdown of
RAGE suppressed cardiac inflammation in both models. We also
demonstrated that the delivery of siRAGE via C-sEVs relieved inflam-
mation more effectively than through N-sEVs (Figures 2 and 4).1028 Molecular Therapy: Nucleic Acids Vol. 24 June 2021We confirmed that C-sEVs were not toxic and retained sEV charac-
teristics even after siRAGE loading (Figure 2). These results support
the clinical introduction of C-sEVs for cardiac-targeted drug delivery.
While the current work focused on inflammatory heart diseases, the
approach described herein may be applied to a variety of other heart
diseases. Furthermore, as sEVs do not trigger an immune response,
they are promising candidates for clinical use.32 Given its capacity
for targeted delivery, the vesicle-siRNA system should be further
developed, enabling greater therapeutic effects at optimal dosages.
In conclusion, C-sEV U exhibited a 2-fold greater cardiac targeting
efficiency relative to N-sEVs. Furthermore, C-sEV U successfully
achieved siRNA delivery, relieving inflammation in cell and animal
models of inflammatory heart disease. Taken together, the current re-
sults highlight the potential of C-sEVs as molecular delivery vehicles
in the treatment of heart disease.MATERIALS AND METHODS
Cloning
pcDNA GNSTM-3-FLAG-10-Lamp2b-HA was a gift from Joshua
Leonard (#71293, Addgene, MA, USA). The CTP (APWHLSS-
QYSRT) nucleotide sequence (50-GCC CCC TGG CAC CTG TCC
TCC CAG TAC TCC CGG ACC-30) was inserted into this plasmid
using a standard PCR method and the following primers: 50-ACT
ATGGGC AGT GGA GCC CCC TGG CAC CTG TCC TCC CAG
TAC TCC CGG ACC GAC TAT AAA GAT GAC-30 and 50- GTC
ATC TTT ATA GTC GGT CCG GGA GTA CTG GGA GGA CAG
GTG CCA GGG GGC TCC ACT GCC CAT AGT-30. The construct
was confirmed via DNA sequencing.Cell culture and sEV isolation
HEK293 cells (Korean Cell Line Bank, Seoul, Korea) and H9C2 cells
(ATCC, VA, USA) were maintained in Dulbecco’s modified Eagle’s
medium (DMEM, Welgene, Korea) containing 10% fetal bovine
serum (FBS, Young In Frontier, Korea) and 1% penicillin-strepto-
mycin (Gibco, Waltham, MA, USA). Cells were cultured in a humid-
ified incubator at 37C with 5% CO2. HEK293 cells were seeded at
1.5 106 cells/mL in a 100-mm dish 1 day prior to transfection in or-
der to ensure 70%–80% confluence on the next day. CTP-tagged
FLAG-LAMP2b plasmid (16 mg) was transfected using Lipofect-
amine 3000 transfection reagent (Thermo Fisher Scientific, Waltham,
MA, USA) according to the manufacturer’s instructions. Cells stably
expressing CTP-tagged FLAG-LAMP2b were selected with hygrom-
ycin B and identified via western blotting with an anti-FLAG
antibody. Cell lines constitutively expressing the CTP-tagged
FLAG-LAMP2b plasmid were seeded at 5  106 cells in a 15-cm
dish. The cell culture medium was serum-free DMEM supplemented
with GlutaMAX (1% final concentration, Gibco). Supernatants were
harvested for sEV isolation after 48 h of culture. Cell debris and mi-
crovesicles were eliminated from the culture medium via sequential
centrifugation, and supernatants were concentrated using a TFF
(tangential flow filtration) system with Sartorius 10-kDa (5 L) poly-
ether sulfone membranes.17 Finally, the sEV fraction was obtained
Figure 4. Effects of siRAGE-loaded C-sEV U in a rat EAM model
To induce myocarditis, rats were immunized with purified cardiac myosin derived from porcine ventricular muscle. On days 0 and 7, each rat was subcutaneously injected
with an emulsion (0.2 mL) containing cardiac myosin (1.0 mg) in the footpads. On day 7, siRAGE-loaded N-sEVs, C-sEV U, or PBS (control group) was administered. (A)
Representative H&E-stained sections of hearts from all four groups. (B) Representative M-mode echocardiograms and comparison of LVEF, LVEDD, and LVESD. (C)
Western blot analysis of RAGE, IL-6, TNF- a, COX2, HMGB1, p-p65, p65, and GAPDH. Values are expressed as mean ± SEM. *p < 0.05 (compared to normal); yp < 0.05
(compared to N-sEVs).
www.moleculartherapy.orgthrough micro-ultracentrifugation at 100,000  g for 2 h at 4C
(Figure 1A).
Western blot analysis
Western blotting was performed as previously described.17 Briefly,
ultracentrifuged sEV pellets, H9C2 cells, or rat tissues were lysed
with radioimmunoprecipitation buffer (ATTO, New York, NY,
USA) containing a protease inhibitor cocktail (ATTO). The total
protein content was determined via a 660 nm protein assay (Pierce,
MA, USA), and equal amounts (20 mg) of sEV, H9C2 cell, or rat tis-
sue protein were separated through sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis and electrotransferred onto polyviny-
lidene fluoride membranes. The blots were probed with anti-FLAG(Sigma, Germany), anti-Lamp2 (SC-18822, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), anti-CD81 (SC-166029, Santa
Cruz Biotechnology), anti-Alix (SC-99010, Santa Cruz Biotech-
nology), anti-RAGE (ab3611, Abcam, Cambridge, UK), anti-IL-6
(SC-57315, Santa Cruz Biotechnology), anti-COX2 (#4842, Cell
Signaling Technology), anti-HMGB1 (#3935, Cell Signaling Tech-
nology), anti-p65 (SC-8008, Santa Cruz Biotechnology), p-p65
(SC-136548, Santa Cruz Biotechnology), or anti-TNF-a (#3707,
Cell Signaling Technology) at 4C overnight. The membranes
were then probed with horseradish peroxidase-conjugated
mouse or rabbit anti-mouse secondary antibodies (Santa Cruz
Biotechnology). The protein bands were visualized using chemilu-
minescence (Advansta, Menlo Park, CA, USA).Molecular Therapy: Nucleic Acids Vol. 24 June 2021 1029
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The DLS machine (DLS7000, Otsuka Electronics, Kyoto, Japan) used
in this study had a goniometer with a 35-mWHe-Ne laser of 633-nm
wavelength. The measurements were performed at a scattering angle
of 165. Light scattering was measured at a controlled temperature of
25.0C. The values reported in this paper are presented as the average
of three replicates. sEVs resuspended in PBS were further diluted with
5 mL of distilled water to determine their size and distribution using
an ELS-Z (Otsuka Electronics).
A formvar-carbon-coated electron microscope grid was placed with
the formvar side down on top of sEV drops for approximately
1 min. The grid was removed, blotted with filter paper, and placed
on a drop of 2% uranyl acetate for 15 s. The excess uranyl acetate
was removed, and the electron microscope grid was examined and
imaged for TEM. All thin sections were then observed under a
TEM (JEM-1011; JEOL, Tokyo, Japan) at an acceleration voltage of
80 kV. Images were captured with a side-mounted Megaview III cam-
era (Soft Imaging System, Münster, Germany).36
Immunocytochemistry and confocal microscopy
Immunocytochemistry and confocal microscopy were performed as
previously described.17 After treatment with or without sEVs for 24
h, H9C2 cells were fixed with 4% paraformaldehyde for 60 min at
15–20C and washed with PBS. Nuclei were stained with 40,6-diami-
dino-2-phenylindole (DAPI) (Santa Cruz Biotechnology). Fluores-
cence microscopy images were obtained under a Zeiss LSM 710
confocal microscope with three excitation filters (405, 488, and
543 nm). Data were recorded as serial optical sections, each consisting
of 1,024  1,024 pixels, overlaid to distinguish separate emission
channels, and saved as TIFF (tagged image file format) files.
PKH26, Alexa Fluor 488, and DAPI fluorescence intensities were
quantified using the RGB function histogram in ImageJ (National In-
stitutes of Health, Bethesda, MD, USA). Sections were analyzed in
triplicate, and the average values were considered.
qRT-PCR analysis
Total RNA was extracted from cultured cells and rat tissues using an
RNeasy mini kit (QIAGEN, Hilden, Germany) in accordance with
the manufacturer’s instructions. cDNA was synthesized using a
high-capacity cDNA reverse transcription kit (Applied Biosystems,
Foster City, CA, USA) in accordance with the manufacturer’s in-
structions. qRT-PCR was performed using an AriaMx real-time
PCR system and Brilliant III Ultra-Fast SYBR Green qPCR master
mix (both Agilent Technologies, Santa Clara, CA, USA). The reac-
tion conditions were as follows: 95C for 3 min, followed by 40 cy-
cles at 95C for 3 s and 55C for 20 s. The following PCR primers
were synthesized by Cosmo Genetech (Daejeon, Korea): RAGE (for-
ward, 50-GAA TCC TCC CCA ATG GTT CA-30; reverse, 50-GCC
CGA CAC CGG AAA GT-30) and b-actin (forward, 50-ATC TGG
CAC CAC ACC TTC-30; reverse, 50-AGC CAG GTC CAG ACG
CA-30). The relative expression levels of RAGE mRNA were calcu-
lated via the 2DDCT method37 and normalized against those of
b-actin.1030 Molecular Therapy: Nucleic Acids Vol. 24 June 2021ELISA analysis
IL-6 level in cell culture medium was measured using a fluorometric
analysis kit according to the manufacturer’s recommendations (Ab-
cam). The samples were analyzed with a plate reader by determining
optical density (OD) at a wavelength of 405 nm. Measurements were
conducted in triplicate.
Cell proliferation assay and H&E staining
The cytotoxic potential of sEVs was assessed using an MTS assay
(Promega,Madison,WI, USA) in accordance with themanufacturer’s
instructions. H9C2 cells were added to 96-well plates and treated with
sEVs in triplicate. Cell survival was determined using an ELISA plate
reader (Molecular Devices, Menlo Park, CA, USA). Rat tissues were
fixed with 4% formaldehyde, dehydrated with alcohol, embedded in
paraffin, chopped into 5-mm slices, and then stained with H&E. Im-
ages of ventricular sections from the four groups of rats were made at
400 magnification (Olympus CX31) and analyzed using ImageJ.
Loading of sEVs with siRNA
The NC-siRNA and siRNA targeting rat RAGE (sense, 50-CUC UAC
GAU CCC AAU UCA A dTdT-30; antisense, 50-UUG AAU UGG
GAU CGU AGA G dTdG-30)38 were obtained from Bioneer (Dae-
jeon, Korea) and transfected into sEVs using Exo-Fect (System Bio-
sciences, Mountain View, CA, USA) in accordance with the manufac-
turer’s instructions. Thereafter, sEVs were incubated with RNase A
(Sigma) and washed twice with cold PBS using Amicon ultra centri-
fugation tubes (EMDMillipore, Billerica, MA, USA). siRNA retention
in sEVs was assessed by measuring fluorescence at a maximum exci-
tation emission spectrum of 493–517 nm on a FlexStation 3 fluores-
cence microplate reader (Molecular Devices). Fluorescence in each
sample was compared with the input of FAM-NC-siRNA alone.
Animal Experiments
Male SD rats (weighing 200–250 g each) were purchased from Orient
Bio (Seongnam, Korea). All animal experiments were approved by the
Institutional Animal Care and Use Committee of Yonsei University
College of Medicine (YUMC-2019-0256) and were conducted in
accordance with the National Institutes of Health Guidelines for the
Care and Use of Laboratory Animals.
We injected 100 mg of PKH26-labeled sEVs per rat (n = 3). After 24 h,
the heart, liver, spleen, and kidney of each rat were harvested, and the
IVIS Spectrum imaging system (PerkinElmer, Waltham, MA, USA)
was used to capture near-infrared fluorescence (NIRF) images. Or-
gans were imaged at an excitation wavelength of 551 nm and fluores-
cence emission at 567 nm. PKH26-related fluorescence signals were
distinguished from autofluorescence signals using Living Image soft-
ware (PerkinElmer).
EAM was induced in SD rats by immunization with porcine cardiac
myosin, as previously described.39 In particular, we administered pu-
rified cardiac myosin (M0531, Sigma) from porcine ventricular mus-
cle. Purified cardiac myosin was emulsified with an equal volume of
Freund’s complete adjuvant (FCA) (F5881, Sigma) containing 1 mg
www.moleculartherapy.orgofMycobacterium tuberculosis (H37Ra, ATCC 25177) at a concentra-
tion of 10 mg/mL. On days 0 and 7, rats were subcutaneously injected
with 0.2 mL of emulsion in the footpads, for a total of 1.0 mg cardiac
myosin per rat. The rats in the normal group received only FCA in the
same manner. On day 7, the rats were administered siRAGE-loaded
N-sEVs or C-sEV U via tail vein injection. Rats in the normal and
PBS groups were treated with equivalent volumes of saline. Three
weeks after immunization, echocardiography, H&E staining, and
western blot analysis were performed to assess normal, myocarditis,
N-sEV-, or C-sEV U-injected rats (each n = 4).
Echocardiography was performed using a Vevo 2100 system (Visual-
Sonics, Toronto, ON, Canada). The left ventricular ejection fraction
(LVEF) was calculated according to the following formulas: LVEF
(%) = [left ventricular end-diastolic volume (LVEDV)  left ventric-
ular end-systolic volume (LVESV)/LVEDV]  100; left ventricular
fractional shortening (LVFS) (%) = [left ventricular internal-diastolic
diameter (LVIDD)  left ventricular internal-systolic diameter
(LVISD)/LVIDD]  100.Immunohistochemistry
Rat hearts were fixed, dehydrated, frozen, and then sliced into 8 mm-
thick cryosections. The sections were incubated with anti-cTnI
(1:100; ab47003, Abcam), anti-vWF (1:100; ab6994, Abcam), and
anti-vimentin (1:250; ab92547, Abcam) overnight at 4C in a wet,
dark box. Subsequently, sections were incubated with a secondary
antibody (Alexa Fluor 488-goat anti-rabbit, 1:500; ab150077, Abcam)
for 1 h at room temperature.Statistical analysis
Data are expressed as the mean ± standard error of the mean (SEM).
For multiple comparison analyses, a one-way analysis of variance
(ANOVA), followed by a Bonferroni correction, was used. Be-
tween-group comparisons were performed via an independent t
test. A p value of <0.05 was considered statistically significant. All sta-
tistical analyses were conducted using SPSS version 23.0 (SPSS).SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.
1016/j.omtn.2021.04.018.ACKNOWLEDGMENTS
This study was supported by research grants from the Basic Science
Research Program through the National Research Foundation of Ko-
rea funded by the Ministry of Education, Science and Technology
(NRF-2017R1A2B3003303) and from the Korean Healthcare Tech-
nology R&D Project funded by the Ministry of Health & Welfare
(HI16C0058), as well as by a CMB-Yuhan research grant from Yonsei
University College of Medicine for 2019 (6-2019-0124). The authors
thank Medical Illustration & Design, part of the Medical Research
Support Services of Yonsei University College of Medicine, for all
artistic support related to this work.AUTHOR CONTRIBUTIONS
B.J. and N.Y. conceived and designed the project. B.J. supervised and
developed the study. H.K. wrote the manuscript. H.K, D.M., and J.-
Y.K. performed the experiments and analyzed the data. S.-H.L. helped
to revise the manuscript.
DECLARATION OF INTERESTS
The authors declare no competing interests.
REFERENCES
1. Rayamajhi, S., Nguyen, T.D.T., Marasini, R., and Aryal, S. (2019). Macrophage-
derived exosome-mimetic hybrid vesicles for tumor targeted drug delivery. Acta
Biomater. 94, 482–494.
2. Abels, E.R., and Breakefield, X.O. (2016). Introduction to extracellular vesicles:
Biogenesis, RNA cargo selection, content, release, and uptake. Cell. Mol.
Neurobiol. 36, 301–312.
3. Maas, S.L.N., Breakefield, X.O., and Weaver, A.M. (2017). Extracellular vesicles:
Unique intercellular delivery vehicles. Trends Cell Biol. 27, 172–188.
4. Takenaka, T., Nakai, S., Katayama, M., Hirano, M., Ueno, N., Noguchi, K., Takatani-
Nakase, T., Fujii, I., Kobayashi, S.S., and Nakase, I. (2019). Effects of gefitinib treat-
ment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell
lung cancer cells. Int. J. Pharm. 572, 118762.
5. Kowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J.P., Primdal-Bengtson, B.,
Dingli, F., Loew, D., Tkach, M., and Théry, C. (2016). Proteomic comparison defines
novel markers to characterize heterogeneous populations of extracellular vesicle sub-
types. Proc. Natl. Acad. Sci. USA 113, E968–E977.
6. Ageta, H., and Tsuchida, K. (2019). Post-translational modification and protein sort-
ing to small extracellular vesicles including exosomes by ubiquitin and UBLs. Cell.
Mol. Life Sci. 76, 4829–4848.
7. Wasala, N.B., Shin, J.H., and Duan, D. (2011). The evolution of heart gene delivery
vectors. J. Gene Med. 13, 557–565.
8. Biesbroek, P.S., Beek, A.M., Germans, T., Niessen, H.W., and van Rossum, A.C.
(2015). Diagnosis of myocarditis: Current state and future perspectives. Int. J.
Cardiol. 191, 211–219.
9. Theleman, K.P., Kuiper, J.J., and Roberts, W.C. (2001). Acute myocarditis (predom-
inately lymphocytic) causing sudden death without heart failure. Am. J. Cardiol. 88,
1078–1083.
10. Caforio, A.L., Pankuweit, S., Arbustini, E., Basso, C., Gimeno-Blanes, J., Felix, S.B., Fu,
M., Helio, T., Heymans, S., Jahns, R., et al. (2013). Current state of knowledge on aeti-
ology, diagnosis, management, and therapy of myocarditis: A position statement of
the European Society of Cardiology Working Group on Myocardial and
Pericardial Diseases. Eur. Heart J. 34, 2636–2648, 2648a–2648d.
11. Kim, I.C., Kim, J.Y., Kim, H.A., and Han, S. (2020). COVID-19-related myocarditis in
a 21-year-old female patient. Eur. Heart J. 41, 1859.
12. Błyszczuk, P. (2019). Myocarditis in humans and in experimental animal models.
Front. Cardiovasc. Med. 6, 64.
13. Yang, W.I., Lee, D., Lee, D.L., Hong, S.Y., Lee, S.H., Kang, S.M., Choi, D.H., Jang, Y.,
Kim, S.H., and Park, S. (2014). Blocking the receptor for advanced glycation end
product activation attenuates autoimmune myocarditis. Circ. J. 78, 1197–1205.
14. Arumugam, S., Thandavarayan, R.A., Veeraveedu, P.T., Ma, M., Giridharan, V.V.,
Arozal, W., Sari, F.R., Sukumaran, V., Lakshmanan, A., Soetikno, V., et al. (2012).
Modulation of endoplasmic reticulum stress and cardiomyocyte apoptosis by mul-
berry leaf diet in experimental autoimmune myocarditis rats. J. Clin. Biochem.
Nutr. 50, 139–144.
15. Shanmuganathan, M., Vughs, J., Noseda, M., and Emanueli, C. (2018). Exosomes:
Basic biology and technological advancements suggesting their potential as ischemic
heart disease therapeutics. Front. Physiol. 9, 1159.
16. Le Bras, A. (2018). Exosome-based therapy to repair the injured heart. Nat. Rev.
Cardiol. 15, 382.Molecular Therapy: Nucleic Acids Vol. 24 June 2021 1031
Molecular Therapy: Nucleic Acids17. Kim, H., Yun, N., Mun, D., Kang, J.Y., Lee, S.H., Park, H., Park, H., and Joung, B.
(2018). Cardiac-specific delivery by cardiac tissue-targeting peptide-expressing exo-
somes. Biochem. Biophys. Res. Commun. 499, 803–808.
18. Sun, D., Zhuang, X., Xiang, X., Liu, Y., Zhang, S., Liu, C., Barnes, S., Grizzle, W.,
Miller, D., and Zhang, H.G. (2010). A novel nanoparticle drug delivery system:
The anti-inflammatory activity of curcumin is enhanced when encapsulated in exo-
somes. Mol. Ther. 18, 1606–1614.
19. Mentkowski, K.I., and Lang, J.K. (2019). Exosomes engineered to express a cardio-
myocyte binding peptide demonstrate improved cardiac retention in vivo. Sci. Rep.
9, 10041.
20. French, K.C., Antonyak,M.A., and Cerione, R.A. (2017). Extracellular vesicle docking
at the cellular port: Extracellular vesicle binding and uptake. Semin. Cell Dev. Biol. 67,
48–55.
21. Khongkow, M., Yata, T., Boonrungsiman, S., Ruktanonchai, U.R., Graham, D., and
Namdee, K. (2019). Surface modification of gold nanoparticles with neuron-targeted
exosome for enhanced blood-brain barrier penetration. Sci. Rep. 9, 8278.
22. Murphy, D.E., de Jong, O.G., Brouwer, M., Wood, M.J., Lavieu, G., Schiffelers, R.M.,
and Vader, P. (2019). Extracellular vesicle-based therapeutics: natural versus engi-
neered targeting and trafficking. Exp. Mol. Med. 51, 1–12.
23. Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., and Wood, M.J. (2011).
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes.
Nat. Biotechnol. 29, 341–345.
24. Wang, X., Chen, Y., Zhao, Z., Meng, Q., Yu, Y., Sun, J., Yang, Z., Chen, Y., Li, J., Ma,
T., et al. (2018). Engineered exosomes with ischemic myocardium-targeting peptide
for targeted therapy in myocardial infarction. J. Am. Heart Assoc. 7, e008737.
25. Zahid, M., Phillips, B.E., Albers, S.M., Giannoukakis, N., Watkins, S.C., and Robbins,
P.D. (2010). Identification of a cardiac specific protein transduction domain by in vivo
biopanning using a M13 phage peptide display library in mice. PLoS ONE 5, e12252.
26. Christaki, E., Lazaridis, N., and Opal, S.M. (2012). Receptor for advanced glycation
end products in bacterial infection: Is there a role for immune modulation of receptor
for advanced glycation end products in the treatment of sepsis? Curr. Opin. Infect.
Dis. 25, 304–311.
27. Yu, Y., Yu, Y., Liu, M., Yu, P., Liu, G., Liu, Y., Su, Y., Jiang, H., and Chen, R. (2016).
Ethyl pyruvate attenuated coxsackievirus B3-induced acute viral myocarditis by sup-
pression of HMGB1/RAGE/NF-KB pathway. Springerplus 5, 215.
28. Beit-Yannai, E., Tabak, S., and Stamer, W.D. (2018). Physical exosome:exosome in-
teractions. J. Cell. Mol. Med. 22, 2001–2006.1032 Molecular Therapy: Nucleic Acids Vol. 24 June 202129. Deregibus, M.C., Figliolini, F., D’Antico, S., Manzini, P.M., Pasquino, C., De Lena, M.,
Tetta, C., Brizzi, M.F., and Camussi, G. (2016). Charge-based precipitation of extra-
cellular vesicles. Int. J. Mol. Med. 38, 1359–1366.
30. Chang, M., Chang, Y.J., Chao, P.Y., and Yu, Q. (2018). Exosome purification based on
PEG-coated Fe3O4 nanoparticles. PLoS ONE 13, e0199438.
31. Mendt, M., Kamerkar, S., Sugimoto, H., McAndrews, K.M., Wu, C.C., Gagea, M.,
Yang, S., Blanko, E.V.R., Peng, Q., Ma, X., et al. (2018). Generation and testing of clin-
ical-grade exosomes for pancreatic cancer. JCI Insight 3, e99263.
32. Zhu, X., Badawi, M., Pomeroy, S., Sutaria, D.S., Xie, Z., Baek, A., Jiang, J., Elgamal,
O.A., Mo, X., Perle, K., et al. (2017). Comprehensive toxicity and immunogenicity
studies reveal minimal effects in mice following sustained dosing of extracellular ves-
icles derived from HEK293T cells. J. Extracell. Vesicles 6, 1324730.
33. Maji, S., Yan, I.K., Parasramka, M., Mohankumar, S., Matsuda, A., and Patel, T.
(2017). In vitro toxicology studies of extracellular vesicles. J. Appl. Toxicol. 37,
310–318.
34. Takov, K., Yellon, D.M., and Davidson, S.M. (2017). Confounding factors in vesicle
uptake studies using fluorescent lipophilic membrane dyes. J. Extracell. Vesicles 6,
1388731.
35. Bangert, A., Andrassy, M., Müller, A.M., Bockstahler, M., Fischer, A., Volz, C.H.,
Leib, C., Göser, S., Korkmaz-Icöz, S., Zittrich, S., et al. (2016). Critical role of
RAGE and HMGB1 in inflammatory heart disease. Proc. Natl. Acad. Sci. USA 113,
E155–E164.
36. Kim, S.Y., Kim, H.J., Kim, H.J., Kim, D.H., Han, J.H., Byeon, H.K., Lee, K., and Kim,
C.H. (2018). HSPA5 negatively regulates lysosomal activity through ubiquitination of
MUL1 in head and neck cancer. Autophagy 14, 385–403.
37. Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression data us-
ing real-time quantitative PCR and the 2DDC(T) method. Methods 25, 402–408.
38. Yang, M.J., Ku, S.H., Kim, D., Kim, W.J., Mok, H., Kim, S.H., and Kwon, I.C. (2015).
Enhanced cytoplasmic delivery of RAGE siRNA using bioreducible polyethyleni-
mine-based nanocarriers for myocardial gene therapy. Macromol. Biosci. 15, 1755–
1763.
39. Kodama, M., Matsumoto, Y., Fujiwara, M., Masani, F., Izumi, T., and Shibata, A.
(1990). A novel experimental model of giant cell myocarditis induced in rats by im-
munization with cardiac myosin fraction. Clin. Immunol. Immunopathol. 57,
250–262.
